Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 318

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Meta-analyses of FibroTest diagnostic value in chronic liver disease

Open access
Poynard, Thierry, Morra, Rachel, Halfon, Philippe, Castera, Laurent, Ratziu, Vlad, Imbert-Bismut, Françoise, Naveau, Sylvie, Thabut, Dominique, Lebrec, Didier, Zoulim, Fabien, Bourliere, Marc, Cacoub, Patrice, Messous, Djamila, Munteanu, Mona, de Ledinghen, Victor·2007·BMC Gastroenterology

Abstract

BACKGROUND: FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients with chronic hepatitis C (CHC). The aim was to test two hypotheses, one, that the FT diagnostic value was similar in the three other frequent fibrotic diseases: chronic hepatitis B (CHB), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD); and the other, that the FT diagnostic value was similar for intermediate and extreme fibrosis stages. METHODS: The main end points were the FT area under the ROC curves (AUROCs) for the diagnosis of bridging fibrosis (F2F3F4 vs. F0F1), standardized for the spectrum of fibrosis stages, and the comparison of FT AUROCs between adjacent stages. Two meta-analyses were performed: one combining all the published studies (random model), and one of an integrated data base combining individual data. Sensitivity analysis integrated the independency of authors, lenght of biopsy, prospective design, respect of procedures, comorbidities, and duration between biopsy and serum sampling. RESULTS: A total of 30 studies were included which pooled 6,378 subjects with both FT and biopsy (3,501 HCV, 1,457 HBV, 267 NAFLD, 429 ALD, and 724 mixed). Individual data were analyzed in 3,282 patients. The mean standardized AUROC was 0.84 (95% CI, 0.83-0.86), without differences between causes of liver disease: HCV 0.85 (0.82-0.87), HBV 0.80 (0.77-0.84), NAFLD 0.84 (0.76-0.92), ALD 0.86 (0.80-0.92), mixed 0.85 (0.80-0.93). The AUROC for the diagnosis of the intermediate adjacent stages F2 vs. F1 (0.66; 0.63-0.68, n = 2,055) did not differ from that of the extreme stages F3 vs. F4 (0.69; 0.65-0.72, n = 817) or F1 vs. F0 (0.62; 0.59-0.65, n = 1788). CONCLUSION: FibroTest is an effective alternative to biopsy in patients with chronic hepatitis C and B, ALD and NAFLD. The FT diagnostic value is similar for the diagnosis of intermediate and extreme fibrosis stages.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-230x-7-40

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 318

Metadata

Authors
Poynard, T., Morra, R., Halfon, P., Castera, L., Ratziu, V., Imbert-Bismut, F., Naveau, S., Thabut, D., Lebrec, D., Zoulim, F., Bourliere, M., Cacoub, P., Messous, D., Munteanu, M., & de Ledinghen, V.
Venue
BMC Gastroenterology
Published
2007-10-15
Volume
7
Issue
1
Pages
40-40
ISSN
1471-230X (ISSN-L)
OpenAlex
W2163381666
Cited by
318
References
45
FWCI
17.38
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meta-analyses of FibroTest diagnostic value in chronic liver disease. https://app.cochat.ai/papers/10.1186/1471-230x-7-40
The paper
Poynard, T., Morra, R., Halfon, P., Castera, L., Ratziu, V., Imbert-Bismut, F., Naveau, S., Thabut, D., Lebrec, D., Zoulim, F., Bourliere, M., Cacoub, P., Messous, D., Munteanu, M., & de Ledinghen, V. (2007). Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterology. https://doi.org/10.1186/1471-230x-7-40

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.